Steven J Frank

List of Publications by Year
in descending order

369 papers	11,433 citations	32410 55 h-index	58552 86 g-index
378 all docs	378 docs citations	378 times ranked	11822 citing authors

#	Article	IF	Citations
1	Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets. Clinical Cancer Research, 2023, 27, 852-864.	3.2	61
2	Improving efficiency and reducing costs of MRI-Guided prostate brachytherapy using Time-Driven Activity-Based costing. Brachytherapy, 2022, 21, 49-54.	0.2	2
3	Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified. Cancer, 2022, 128, 509-518.	2.0	10
4	American Brachytherapy Society radiation oncology alternative payment model task force: Quality measures and metrics for brachytherapy. Brachytherapy, 2022, 21, 63-74.	0.2	3
5	Proton Image-guided Radiation Assignment for Therapeutic Escalation via Selection of locally advanced head and neck cancer patients [PIRATES]: A Phase I safety and feasibility trial of MRI-guided adaptive particle radiotherapy. Clinical and Translational Radiation Oncology, 2022, 32, 35-40.	0.9	3
6	The influence of radiation dose on taste impairment in a prospective observational study cohort of oropharyngeal cancer patients. Acta OncolÃ³gica, 2022, 61, 146-152.	0.8	1
7	Driving accountable care with brachytherapy. Brachytherapy, 2022, 21, 4-5.	0.2	0
8	Prospective Evaluation of Prostate and Organs at Risk Segmentation Software for MRI-based Prostate Radiation Therapy. Radiology: Artificial Intelligence, 2022, 4, e210151.	3.0	7
9	Comprehensive Quantitative Evaluation of Variability in Magnetic Resonance-Guided Delineation of Oropharyngeal Gross Tumor Volumes and High-Risk Clinical Target Volumes: An R-IDEAL Stage 0 Prospective Study. International Journal of Radiation Oncology Biology Physics, 2022, 113, 426-436.	0.4	18
10	Computer-aided segmentation on MRI for prostate radiotherapy, Part I: Quantifying human interobserver variability of the prostate and organs at risk and its impact on radiation dosimetry. Radiotherapy and Oncology, 2022, 169, 124-131.	0.3	7
11	Computer-aided segmentation on MRI for prostate radiotherapy, part II: Comparing human and computer observer populations and the influence of annotator variability on algorithm variability. Radiotherapy and Oncology, 2022, 169, 132-139.	0.3	3
12	Unilateral Radiotherapy for Tonsillar Cancer: Treatment Outcomes in the Era of Human Papilloma Virus (HPV), Positron-emission Tomography (PET) and Intensity-modulated Radiation Therapy (IMRT). International Journal of Radiation Oncology Biology Physics, 2022, , .	0.4	6
13	Predictive performance of different NTCP techniques for radiation-induced esophagitis in NSCLC patients receiving proton radiotherapy. Scientific Reports, 2022, 12, .	1.6	4
14	Health Care Resource Utilization for Esophageal Cancer Using Proton versus Photon Radiation Therapy. International Journal of Particle Therapy, 2022, 9, 18-27.	0.9	1
15	Principles of radiobiology. , 2021, , 1-13.e6.		1
16	Technological advancements and outlook in proton therapy. , 2021, , 215-220.e5.		0
17	The University of Texas MD Anderson cancer centerâ€™s recommended proton therapy indications. , 2021, , 221-250.		0
18	Prognostic significance of pre-treatment neutrophil-to-lymphocyte ratio (NLR) in patients with oropharyngeal cancer treated with radiotherapy. British Journal of Cancer, 2021, 124, 628-633.	2.9	17

#	Article	IF	Citations
19	Dosimetric impact of commercial CT metal artifact reduction algorithms and a novel inâ€house algorithm for proton therapy of head and neck cancer. Medical Physics, 2021, 48, 445-455.	1.6	3
20	Development and validation of a contouring guideline for the taste bud bearing tongue mucosa. Radiotherapy and Oncology, 2021, 157, 63-69.	0.3	4
21	Influence of Geography on Prostate Cancer Treatment. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1286-1295.	0.4	19
22	Conditional survival among patients with oropharyngeal cancer treated with radiation therapy and alive without recurrence 5 years after diagnosis. Cancer, 2021, 127, 1228-1237.	2.0	2
23	Longitudinal characterization of the tumoral microbiome during radiotherapy in HPV-associated oropharynx cancer. Clinical and Translational Radiation Oncology, 2021, 26, 98-103.	0.9	7
24	Evaluation of image quality of a novel computed tomography metal artifact management technique on an anthropomorphic head and neck phantom. Physics and Imaging in Radiation Oncology, 2021, 17, 111-116.	1.2	7
25	Fully Balanced SSFP Without an Endorectal Coil for Postimplant QA of MRI-Assisted Radiosurgery (MARS) of Prostate Cancer: A Prospective Study. International Journal of Radiation Oncology Biology Physics, 2021, 109, 614-625.	0.4	7
26	The Emerging Potential of Multi-Ion Radiotherapy. Frontiers in Oncology, 2021, 11, 624786.	1.3	26
27	Outcomes after salvage for HPV-positive recurrent oropharyngeal cancer treated with primary radiation. Oral Oncology, 2021, 113, 105125.	0.8	12
28	The Reality of Randomized Controlled Trials for Assessing the Benefit of Proton Therapy: Critically Examining the Intent-to-Treat Principle in the Presence of Insurance Denial. Advances in Radiation Oncology, 2021, 6, 100635.	0.6	3
29	Outcomes of patients with oropharyngeal squamous cell carcinoma treated with induction chemotherapy followed by concurrent chemoradiation compared with those treated with concurrent chemoradiation. Cancer, 2021, 127, 2916-2925.	2.0	5
30	Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores â€“ A pooled analysis of RTOG 0129 and 0522. Oral Oncology, 2021, 116, 105241.	0.8	6
31	Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress. Molecular Cancer Therapeutics, 2021, 20, 1257-1269.	1.9	15
32	Financial Toxicity in Head and Neck Cancer Patients Treated With Proton Therapy. International Journal of Particle Therapy, 2021, 8, 366-373.	0.9	6
33	Proton Therapy for Major Salivary Gland Cancer: Clinical Outcomes. International Journal of Particle Therapy, 2021, 8, 261-272.	0.9	4
34	Proton Beam Therapy for Head and Neck Carcinoma of Unknown Primary: Toxicity and Quality of Life. International Journal of Particle Therapy, 2021, 8, 234-247.	0.9	4
35	Cost-Effectiveness Models of Proton Therapy for Head and Neck: Evaluating Quality and Methods to Date. International Journal of Particle Therapy, 2021, 8, 339-353.	0.9	5
36	Developing a Value Framework: Utilizing Administrative Data to Assess an Enhanced Care Initiative. Journal of Surgical Research, 2021, 262, 115-120.	0.8	10

#	Article	IF	Citations
37	Proton Radiotherapy to Reduce Late Complications in Childhood Head and Neck Cancers. International Journal of Particle Therapy, 2021, 8, 155-167.	0.9	4
38	A Review of Particle Therapy for Skull Base Tumors: Modern Considerations and Future Directions. International Journal of Particle Therapy, 2021, 8, 168-178.	0.9	5
39	Patient-Reported Outcomes after Intensity-Modulated Proton Therapy for Oropharynx Cancer. International Journal of Particle Therapy, 2021, 8, 213-222.	0.9	2
40	NTCP Modeling of Late Effects for Head and Neck Cancer: A Systematic Review. International Journal of Particle Therapy, 2021, 8, 95-107.	0.9	9
41	The Role of Particle Therapy in Adenoid Cystic Carcinoma and Mucosal Melanoma of the Head and Neck. International Journal of Particle Therapy, 2021, 8, 273-284.	0.9	10
42	Non-canonical function of DGCR8 in DNA double-strand break repair signaling and tumor radioresistance. Nature Communications, 2021, 12, 4033.	5.8	12
43	Proton Therapy for HPV-Associated Oropharyngeal Cancers of the Head and Neck: a De-Intensification Strategy. Current Treatment Options in Oncology, 2021, 22, 54.	1.3	11
44	The Biological Basis for Enhanced Effects of Proton Radiation Therapy Relative to Photon Radiation Therapy for Head and Neck Squamous Cell Carcinoma. International Journal of Particle Therapy, 2021, 8, 3-13.	0.9	10
45	Proton Therapy for Head and Neck Cancer: A 12-Year, Single-Institution Experience. International Journal of Particle Therapy, 2021, 8, 108-118.	0.9	8
46	Bioelectrical impedance analysis as a quantitative measure of sarcopenia in head and neck cancer patients treated with radiotherapy. Radiotherapy and Oncology, 2021, 159, 21-27.	0.3	12
47	Activity-Based Costing of Intensity-Modulated Proton versus Photon Therapy for Oropharyngeal Cancer. International Journal of Particle Therapy, 2021, 8, 374-382.	0.9	4
48	Work Outcomes after Intensity-Modulated Proton Therapy (IMPT) versus Intensity-Modulated Photon Therapy (IMRT) for Oropharyngeal Cancer. International Journal of Particle Therapy, 2021, 8, 319-327.	0.9	11
49	PTCOG Head and Neck Subcommittee Consensus Guidelines on Particle Therapy for the Management of Head and Neck Tumors. International Journal of Particle Therapy, 2021, 8, 84-94.	0.9	3
50	18FDG positron emission tomography mining for metabolic imaging biomarkers of radiation-induced xerostomia in patients with oropharyngeal cancer. Clinical and Translational Radiation Oncology, 2021, 29, 93-101.	0.9	6
51	Stereotactic body ablative radiotherapy for reirradiation of small volume head and neck cancers is associated with prolonged survival: Large, singleâ€institution, modern cohort study. Head and Neck, 2021, 43, 3331-3344.	0.9	15
52	Intensity-modulated proton therapy for oropharyngeal cancer reduces rates of late xerostomia. Radiotherapy and Oncology, 2021, 160, 32-39.	0.3	18
53	Low dose rate brachytherapy for primary treatment of localized prostate cancer: A systemic review and executive summary of an evidence-based consensus statement. Brachytherapy, 2021, 20, 1114-1129.	0.2	26
54	Biology of the Radio- and Chemo-Responsiveness in HPV Malignancies. Seminars in Radiation Oncology, 2021, 31, 274-285.	1.0	13

#	Article	IF	Citations
55	Communicating Value: Use of a Novel Framework in the Assessment of an Enhanced Recovery Initiative. Annals of Surgery, 2021, 273, e7-e9.	2.1	9
56	Referral Patterns and Treatment Delays in Medulloblastoma: A Large Academic Proton Center Experience. International Journal of Particle Therapy, 2021, 7, 1-10.	0.9	6
57	Risk stratification after recurrence of human papillomavirus (HPV) â€related and nonâ€HPV â€related oropharyngeal cancer: A secondary analysis of NRG Oncology RTOG 0129 and 0522. Head and Neck, 2021, 44, 158.	0.9	3
58	Outcomes of carotidâ€sparing IMRT for T1 glottic cancer: Comparison with conventional radiation. Laryngoscope, 2020, 130, 146-153.	1.1	25
59	Longâ€term quality of life after definitive treatment of sinonasal and nasopharyngeal malignancies. Laryngoscope, 2020, 130, 86-93.	1.1	17
60	Minocycline for symptom reduction during radiation therapy for head and neck cancer: a randomized clinical trial. Supportive Care in Cancer, 2020, 28, 261-269.	1.0	12
61	Radiation-Induced Hypothyroidism After Radical Intensity Modulated Radiation Therapy for Oropharyngeal Carcinoma. Advances in Radiation Oncology, 2020, 5, 111-119.	0.6	14
62	Estimating PTV Margins in Head and Neck Stereotactic Ablative Radiation Therapy (SABR) Through Target Site Analysis of Positioning and Intrafractional Accuracy. International Journal of Radiation Oncology Biology Physics, 2020, 106, 185-193.	0.4	12
63	Patient Outcomes after Reirradiation of Small Skull Base Tumors using Stereotactic Body Radiotherapy, Intensity Modulated Radiotherapy, or Proton Therapy. Journal of Neurological Surgery, Part B: Skull Base, 2020, 81, 638-644.	0.4	7
64	Multiple-CT optimization: An adaptive optimization method to account for anatomical changes in intensity-modulated proton therapy for head and neck cancers. Radiotherapy and Oncology, 2020, 142, 124-132.	0.3	28
65	Patterns of protein expression in human head and neck cancer cell lines differ after proton vs photon radiotherapy. Head and Neck, 2020, 42, 289-301.	0.9	11
66	Xerostomia-related quality of life for patients with oropharyngeal carcinoma treated with proton therapy. Radiotherapy and Oncology, 2020, 142, 133-139.	0.3	21
67	MRI-assisted radiosurgery: A quality assurance nomogram for palladium-103 and iodine-125 prostate brachytherapy. Brachytherapy, 2020, 19, 38-42.	0.2	3
68	A prospective evaluation of healthâ€related quality of life after skull base reâ€irradiation. Head and Neck, 2020, 42, 485-497.	0.9	3
69	Surveillance imaging for patients with head and neck cancer treated with definitive radiotherapy: A partially observed Markov decision process model. Cancer, 2020, 126, 749-756.	2.0	8
70	Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends. Cancer, 2020, 126, 506-514.	2.0	21
71	Transitioning from measurement-based to combined patient-specific quality assurance for intensity-modulated proton therapy. British Journal of Radiology, 2020, 93, 20190669.	1.0	6
72	Developing an intraoperative 3T MRI-guided brachytherapy program within a diagnostic imaging suite: Methods, process workflow, and value-based analysis. Brachytherapy, 2020, 19, 427-437.	0.2	12

#	Article	IF	Citations
73	Patterns of Failure After Intensity Modulated Radiation Therapy in Head and Neck Squamous Cell Carcinoma of Unknown Primary: Implication of Elective Nodal and Mucosal Dose Coverage. Advances in Radiation Oncology, 2020, 5, 929-935.	0.6	8
74	Machine Segmentation of Pelvic Anatomy in MRI-Assisted Radiosurgery (MARS) for Prostate Cancer Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2020, 108, 1292-1303.	0.4	18
75	Outcomes and patterns of radiation associated brain image changes after proton therapy for head and neck skull base cancers. Radiotherapy and Oncology, 2020, 151, 119-125.	0.3	10
76	Development of a stereoscopic CT metal artifact management algorithm using gantry angle tilts for head and neck patients. Journal of Applied Clinical Medical Physics, 2020, 21, 120-130.	0.8	9
77	The effects of zinc on radiation-induced dysgeusia: a systematic review and meta-analysis. Supportive Care in Cancer, 2020, 28, 1-12.	1.0	13
78	The impact of tongue-deviating and tongue-depressing oral stents on long-term radiation-associated symptoms in oropharyngeal cancer survivors. Clinical and Translational Radiation Oncology, 2020, 24, 71-78.	0.9	11
79	Predictors of urinary toxicity with MRI-assisted radiosurgery for low-dose-rate prostate brachytherapy. Brachytherapy, 2020, 19, 574-583.	0.2	13
80	Quality comparison between three-dimensional T2-weighted SPACE and two-dimensional T2-weighted turbo spin echo magnetic resonance images for the brachytherapy planning evaluation of prostate and periprostatic anatomy. Brachytherapy, 2020, 19, 484-490.	0.2	7
81	Costs and Complications After a Diagnosis of Prostate Cancer Treated With Time-Efficient Modalities: An Analysis of National Medicare Data. Practical Radiation Oncology, 2020, 10, 282-292.	1.1	5
82	Malignant Mixed Tumor (Carcinoma Ex Pleomorphic Adenoma) of the Lacrimal Gland. Ophthalmic Plastic and Reconstructive Surgery, 2020, 36, 497-502.	0.4	17
83	<scp>Highly conformal</scp> reirradiation in patients with prior oropharyngeal radiation: Clinical efficacy and toxicity outcomes. Head and Neck, 2020, 42, 3326-3335.	0.9	14
84	A Dosimetric Comparison of Oral Cavity Sparing in the Unilateral Treatment of Early Stage Tonsil Cancer: IMRT, IMPT, and Tongue-Deviating Oral Stents. Advances in Radiation Oncology, 2020, 5, 1359-1363.	0.6	7
85	Strategic Operational Redesign for Successfully Navigating Prior Authorization Barriers at a Large-Volume Proton Therapy Center. JCO Oncology Practice, 2020, 16, e1067-e1077.	1.4	6
86	The American Brachytherapy Society prostate brachytherapy LDR/HDR simulation workshops: Hands-on, step-by-step training in the process of quality assurance. Brachytherapy, 2020, 19, 787-793.	0.2	9
87	Comparison of tumor delineation using dual energy computed tomography versus magnetic resonance imaging in head and neck cancer re-irradiation cases. Physics and Imaging in Radiation Oncology, 2020, 14, 1-5.	1.2	9
88	Patient-reported outcomes, physician-reported toxicities, and treatment outcomes in a modern cohort of patients with sinonasal cancer treated using proton beam therapy. Radiotherapy and Oncology, 2020, 148, 258-266.	0.3	21
89	A prospective parallel design study testing non-inferiority of customized oral stents made using 3D printing or manually fabricated methods. Oral Oncology, 2020, 106, 104665.	0.8	6
90	Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate Cancer. JAMA Network Open, 2020, 3, e201255.	2.8	18

#	Article	IF	Citations
91	Prospective observational evaluation of radiation-induced late taste impairment kinetics in oropharyngeal cancer patients: Potential for improvement over time?. Clinical and Translational Radiation Oncology, 2020, 22, 98-105.	0.9	5
92	Proton Reirradiation: Expert Recommendations for Reducing Toxicities and Offering New Chances of Cure in Patients With Challenging Recurrence Malignancies. Seminars in Radiation Oncology, 2020, 30, 253-261.	1.0	18
93	Evaluating single-institution resource costs of consolidative radiotherapy for oligometastatic non-small cell lung cancer using time-driven activity-based costing. Clinical and Translational Radiation Oncology, 2020, 23, 80-84.	0.9	4
94	Data from a terminated study on iron oxide nanoparticle magnetic resonance imaging for head and neck tumors. Scientific Data, 2020, 7, 63.	2.4	6
95	Lymphopenia during radiotherapy in patients with oropharyngeal cancer. Radiotherapy and Oncology, 2020, 145, 95-100.	0.3	18
96	Evaluation of the accuracy of deformable image registration on MRI with a physical phantom. Journal of Applied Clinical Medical Physics, 2020, 21, 166-173.	0.8	13
97	Comparative analysis of acute toxicities and patient reported outcomes between intensity-modulated proton therapy (IMPT) and volumetric modulated arc therapy (VMAT) for the treatment of oropharyngeal cancer. Radiotherapy and Oncology, 2020, 147, 64-74.	0.3	34
98	Proton and photon radiosensitization effects of niraparib, a PARPâ€1/â€2 inhibitor, on human head and neck cancer cells. Head and Neck, 2020, 42, 2244-2256.	0.9	20
99	Prospective longitudinal patient-reported outcomes of swallowing following intensity modulated proton therapy for oropharyngeal cancer. Radiotherapy and Oncology, 2020, 148, 133-139.	0.3	11
100	Evaluation of the high definition field of view option of a large-bore computed tomography scanner for radiation therapy simulation. Physics and Imaging in Radiation Oncology, 2020, 13, 44-49.	1.2	3
101	Neurologic sequelae following radiation with and without chemotherapy for oropharyngeal cancer: Patient reported outcomes study. Head and Neck, 2020, 42, 2137-2144.	0.9	3
102	Stereotactic Body Radiation Therapy for the Definitive Treatment of Early Stage Kidney Cancer: A Survival Comparison With Surgery, Tumor Ablation, and Observation. Advances in Radiation Oncology, 2020, 5, 495-502.	0.6	11
103	SABR for Skull Base Malignancies: A Systematic Analysis of Set-Up and Positioning Accuracy. Practical Radiation Oncology, 2020, 10, 363-371.	1.1	3
104	Three-Year Results of a Prospective Statewide Insurance Coverage Pilot for Proton Therapy: Stakeholder Collaboration Improves Patient Access to Care. JCO Oncology Practice, 2020, 16, e966-e976.	1.4	9
105	Development, implementation, and outcomes of a simulation-based medical education (SBME) prostate brachytherapy workshop for radiation oncology residents. Brachytherapy, 2020, 19, 738-745.	0.2	11
106	Lymanâ€“Kutcherâ€“Burman normal tissue complication probability modeling for radiation-induced esophagitis in non-small cell lung cancer patients receiving proton radiotherapy. Radiotherapy and Oncology, 2020, 146, 200-204.	0.3	12
107	A biochemical definition of cure after brachytherapy for prostate cancer. Radiotherapy and Oncology, 2020, 149, 64-69.	0.3	48
108	Caspase-8 loss radiosensitizes head and neck squamous cell carcinoma to SMAC mimeticâ€“induced necroptosis. JCI Insight, 2020, 5, .	2.3	28

#	Article	IF	Citations
109	Outcomes and Toxicities of Proton and Photon Radiation Therapy for Testicular Seminoma. International Journal of Particle Therapy, 2020, 7, 11-20.	0.9	13
110	Proton Therapy in a Pandemic: An Operational Response to the COVID-19 Crisis. International Journal of Particle Therapy, 2020, 7, 54-57.	0.9	3
111	Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer. Clinical Cancer Research, 2019, 25, 7078-7088.	3.2	21
112	COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms. Clinical Cancer Research, 2019, 25, 5650-5662.	3.2	83
113	Chronic radiation-associated dysphagia in oropharyngeal cancer survivors: Towards age-adjusted dose constraints for deglutitive muscles. Clinical and Translational Radiation Oncology, 2019, 18, 16-22.	0.9	24
114	A Dosimetric Comparison of Oral Cavity Sparing in the Unilateral Treatment of Early Stage Tonsil Cancer: IMRT, IMPT, and Tongue Deviating Oral Stents. International Journal of Radiation Oncology Biology Physics, 2019, 103, E36.	0.4	2
115	Quantifying institutional resource utilization of adjuvant brachytherapy and intensity-modulated radiation therapy for endometrial cancer via time-driven activity-based costing. Brachytherapy, 2019, 18, 445-452.	0.2	16
116	Prospective quantitative quality assurance and deformation estimation of MRI-CT image registration in simulation of head and neck radiotherapy patients. Clinical and Translational Radiation Oncology, 2019, 18, 120-127.	0.9	24
117	Deep learning application engine (DLAE): Development and integration of deep learning algorithms in medical imaging. SoftwareX, 2019, 10, 100347.	1.2	5
118	Defining the Value of MRI-Assisted Radiosurgery (MARS) for Prostate Brachytherapy: A Pilot Study Using Time-Driven Activity-Based Costing. Brachytherapy, 2019, 18, S80.	0.2	2
119	Quantifying the accuracy of deformable image registration for coneâ€beam computed tomography with a physical phantom. Journal of Applied Clinical Medical Physics, 2019, 20, 92-100.	0.8	16
120	Creating customized oral stents for head and neck radiotherapy using 3D scanning and printing. Radiation Oncology, 2019, 14, 148.	1.2	30
121	A Prospective Trial Evaluating Patient Reported Outcomes of Customized Oral Stents for Head and Neck (HN) Radiotherapy (RT) Using 3D Printing and Traditional Methods. International Journal of Radiation Oncology Biology Physics, 2019, 103, E35-E36.	0.4	1
122	Risk of second primary malignancies in head and neck cancer patients treated with definitive radiotherapy. Npj Precision Oncology, 2019, 3, 22.	2.3	31
123	Long-term Outcomes of Globe-Preserving Surgery with Proton Beam Radiation for Adenoid Cystic Carcinoma of the Lacrimal Gland. American Journal of Ophthalmology, 2019, 201, 83-84.	1.7	0
124	Optimizing laryngeal sparing with intensity modulated radiotherapy or volumetric modulated arc therapy for unilateral tonsil cancer. Physics and Imaging in Radiation Oncology, 2019, 10, 29-34.	1.2	2
125	Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial. International Journal of Radiation Oncology Biology Physics, 2019, 104, 790-797.	0.4	56
126	Development and clinical implementation of SeedNet: A slidingâ€window convolutional neural network for radioactive seed identification in MRIâ€assisted radiosurgery (MARS). Magnetic Resonance in Medicine, 2019, 81, 3888-3900.	1.9	15

#	Article	IF	Citations
127	Fixed- versus Variable-RBE Computations for Intensity Modulated Proton Therapy. Advances in Radiation Oncology, 2019, 4, 156-167.	0.6	14
128	The Insurance Approval Process for Proton Radiation Therapy: A Significant Barrier to Patient Care. International Journal of Radiation Oncology Biology Physics, 2019, 104, 724-733.	0.4	47
129	Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy. Cancer, 2019, 125, 1823-1829.	2.0	28
130	Multi-Tasking Neural Networks for Anatomy Segmentation in Prostate Brachytherapy MRI. Brachytherapy, 2019, 18, S16.	0.2	3
131	A prospective longitudinal assessment of MRI signal intensity kinetics of non-target muscles in patients with advanced stage oropharyngeal cancer in relationship to radiotherapy dose and post-treatment radiation-associated dysphagia: Preliminary findings from a randomized trial. Radiotherapy and Oncology, 2019, 130, 46-55.	0.3	14
132	Proton versus photon radiationâ€“induced cell death in head and neck cancer cells. Head and Neck, 2019, 41, 46-55.	0.9	23
133	Intensity modulated proton therapy (IMPT) â€“ The future of IMRT for head and neck cancer. Oral Oncology, 2019, 88, 66-74.	0.8	103
134	Characterization of a new physical phantom for testing rigid and deformable image registration. Journal of Applied Clinical Medical Physics, 2019, 20, 145-153.	0.8	12
135	Fatigue following radiation therapy in nasopharyngeal cancer survivors: A dosimetric analysis incorporating patient report and observer rating. Radiotherapy and Oncology, 2019, 133, 35-42.	0.3	16
136	Radiographic retropharyngeal lymph node involvement in HPVâ€associated oropharyngeal carcinoma: Patterns of involvement and impact on patient outcomes. Cancer, 2019, 125, 1536-1546.	2.0	19
137	Stereotactic radiosurgery for trigeminal pain secondary to recurrent malignant skull base tumors. Journal of Neurosurgery, 2019, 130, 812-821.	0.9	6
138	Hydrogel Spacer Reduces Rectal Dose during Proton Therapy for Prostate Cancer: A Dosimetric Analysis. International Journal of Particle Therapy, 2019, 5, 23-31.	0.9	8
139	Outcomes of patients diagnosed with carcinoma metastatic to the neck from an unknown primary source and treated with intensityâ€modulated radiation therapy. Cancer, 2018, 124, 1415-1427.	2.0	18
140	Comparison of prostate distortion by inflatable and rigid endorectal MRI coils in permanent prostate brachytherapy imaging. Brachytherapy, 2018, 17, 298-305.	0.2	7
141	Patient-reported health-related quality of life for men treated with low-dose-rate prostate brachytherapy as monotherapy with 125-iodine, 103-palladium, or 131-cesium: Results of a prospective phase II study. Brachytherapy, 2018, 17, 265-276.	0.2	12
142	A methodology to investigate the impact of image distortions on the radiation dose when using magnetic resonance images for planning. Physics in Medicine and Biology, 2018, 63, 085005.	1.6	17
143	Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer. Oral Oncology, 2018, 79, 1-8.	0.8	6
144	Patient-reported Urinary, Bowel, and Sexual Function After Hypofractionated Intensity-modulated Radiation Therapy for Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 558-567.	0.6	27

#	Article	IF	Citations
145	Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes. International Journal of Radiation Oncology Biology Physics, 2018, 100, 374-382.	0.4	42
146	Magnetic Resonance Imaging-Guided Adaptive Radiation Therapy: A â€œGame Changerâ€•for Prostate Treatment?. International Journal of Radiation Oncology Biology Physics, 2018, 100, 361-373.	0.4	132
147	Quality of life after brachytherapy or bilateral nerveâ€sparing robotâ€assisted radical prostatectomy for prostate cancer: a prospective cohort. BJU International, 2018, 121, 540-548.	1.3	22
148	Proton Therapy for Head and Neck Cancers. Seminars in Radiation Oncology, 2018, 28, 53-63.	1.0	89
149	Early Stage olfactory neuroblastoma and the impact of resecting dura and olfactory bulb. Laryngoscope, 2018, 128, 1274-1280.	1.1	13
150	Patient reported dry mouth: Instrument comparison and model performance for correlation with quality of life in head and neck cancer survivors. Radiotherapy and Oncology, 2018, 126, 75-80.	0.3	19
151	Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer. Journal of Clinical Oncology, 2018, 36, 1823-1830.	0.8	70
152	Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate Cancer. Journal of Clinical Oncology, 2018, 36, 2943-2949.	0.8	85
153	Radiation-Related Alterations of Taste Function in Patients With Head and Neck Cancer: a Systematic Review. Current Treatment Options in Oncology, 2018, 19, 72.	1.3	49
154	Prognostic factors and survival in adenoid cystic carcinoma of the sinonasal cavity. Head and Neck, 2018, 40, 2596-2605.	0.9	19
155	Toxicity Evaluation of a Novel Magnetic Resonance Imaging Marker, CoCl2-N-Acetylcysteine, in Rats. Journal of Toxicology, 2018, 2018, 1-8.	1.4	0
156	Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching â€˜liquid biopsyâ€™ and quantitative tumor modeling. BMC Cancer, 2018, 18, 903.	1.1	14
157	Significance of Negative Posttreatment 18-FDG PET/CT Imaging in Patients With p16/HPV-Positive Oropharyngeal Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1029-1035.	0.4	18
158	Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial. Clinical and Translational Radiation Oncology, 2018, 13, 19-23.	0.9	41
159	Eye-Preserving Surgery Followed by Adjuvant Radiotherapy for Lacrimal Gland Carcinoma: Outcomes in 37 Patients. Ophthalmic Plastic and Reconstructive Surgery, 2018, 34, 570-574.	0.4	25
160	SeedNet for Automated Detection and Localization of Radioactive Seeds in Post-Implant MRI: A Comparison with and without the use of An Endorectal Coil for Imaging. Brachytherapy, 2018, 17, S80-S81.	0.2	3
161	Reactive Oxygen Species Generation in Human Cells by a Novel Magnetic Resonance Imaging Contrast Agent. Journal of Toxicology, 2018, 2018, 1-7.	1.4	3
162	Comparing Intensity-Modulated Proton Therapy With Intensity-Modulated Photon Therapy for Oropharyngeal Cancer: The Journey From Clinical Trial Concept to Activation. Seminars in Radiation Oncology, 2018, 28, 108-113.	1.0	26

#	Article	IF	Citations
163	MRI guided focal HDR brachytherapy for localized prostate cancer: Toxicity, biochemical outcome and quality of life. Radiotherapy and Oncology, 2018, 129, 554-560.	0.3	18
164	Parallel imaging compressed sensing for accelerated imaging and improved signal-to-noise ratio in MRI-based postimplant dosimetry of prostate brachytherapy. Brachytherapy, 2018, 17, 816-824.	0.2	9
165	Imaging and clinical data archive for head and neck squamous cell carcinoma patients treated with radiotherapy. Scientific Data, 2018, 5, 180173.	2.4	51
166	Prospective Qualitative and Quantitative Analysis of Real-Time Peer Review Quality Assurance Rounds Incorporating Direct Physical Examination for Head and Neck Cancer Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 98, 532-540.	0.4	54
167	Permanent prostate brachytherapy pubic arch evaluation with diagnostic magnetic resonance imaging. Brachytherapy, 2017, 16, 728-733.	0.2	4
168	Use of magnetic resonance imaging in low-dose-rate and high-dose-rate prostate brachytherapy from diagnosis to treatment assessment: Defining the knowledge gaps, technical challenges, and barriers to implementation. Brachytherapy, 2017, 16, 672-678.	0.2	15
169	MRI Image-Guided Low-Dose Rate Brachytherapy for Prostate Cancer. , 2017, , 319-344.		3
170	Quantitative pretreatment CT volumetry: Association with oncologic outcomes in patients with T4a squamous carcinoma of the larynx. Head and Neck, 2017, 39, 1609-1620.	0.9	18
171	Prostate brachytherapy, either alone or in combination with external beam radiation, is associated with longer overall survival in men with favorable pathologic Group 4 (Gleason score 8) prostate cancer. Brachytherapy, 2017, 16, 790-796.	0.2	9
172	Permanent prostate brachytherapy postimplant magnetic resonance imaging dosimetry using positive contrast magnetic resonance imaging markers. Brachytherapy, 2017, 16, 761-769.	0.2	9
173	Bending the slope of the brachytherapy curve: Magnetic resonance imaging-assisted radiosurgery for the treatment of prostate cancer. Brachytherapy, 2017, 16, 657-658.	0.2	5
174	Intensity-modulated proton therapy and osteoradionecrosis in oropharyngeal cancer. Radiotherapy and Oncology, 2017, 123, 401-405.	0.3	73
175	Outcomes for olfactory neuroblastoma treated with induction chemotherapy. Head and Neck, 2017, 39, 1671-1679.	0.9	57
176	In Reply to Yamazaki etÂal. International Journal of Radiation Oncology Biology Physics, 2017, 97, 868-869.	0.4	0
177	Pulse sequence considerations for simulation and postimplant dosimetry of prostate brachytherapy. Brachytherapy, 2017, 16, 743-753.	0.2	14
178	Recurrent oral cavity cancer: Patterns of failure after salvage multimodality therapy. Head and Neck, 2017, 39, 633-638.	0.9	16
179	Human papillomavirus status and the relative biological effectiveness of proton radiotherapy in head and neck cancer cells. Head and Neck, 2017, 39, 708-715.	0.9	24
180	Long-term economic value of hypofractionated prostate radiation: Secondary analysis of a randomized trial. Advances in Radiation Oncology, 2017, 2, 249-258.	0.6	21

#	Article	IF	Citations
181	Dose-volume correlates of mandibular osteoradionecrosis in Oropharynx cancer patients receiving intensity-modulated radiotherapy: Results from a case-matched comparison. Radiotherapy and Oncology, 2017, 124, 232-239.	0.3	69
182	MRI-Based Prostate Brachytherapy - Imaging with and without an Endorectal Coil for Post-Implant Quality Assurance. Brachytherapy, 2017, 16, S56.	0.2	5
183	Early Quality of Life Outcomes for MRI-Assisted Prostate Brachytherapy Patients. Brachytherapy, 2017, 16, S108.	0.2	2
184	Automated Prostate Brachytherapy Seed Detection on Post-Implant MRI Using Novel Martin Algorithm. Brachytherapy, 2017, 16, S57.	0.2	2
185	Clinical outcomes after local field conformal reirradiation of patients with retropharyngeal nodal metastasis. Head and Neck, 2017, 39, 2079-2087.	0.9	15
186	Cognitive function and patientâ€reported memory problems after radiotherapy for cancers at the skull base: A crossâ€sectional survivorship study using the Telephone Interview for Cognitive Status and the MD Anderson Symptom Inventoryâ€Head and Neck Module. Head and Neck, 2017, 39, 2048-2056.	0.9	5
187	Prognostic impact of leukocyte counts before and during radiotherapy for oropharyngeal cancer. Clinical and Translational Radiation Oncology, 2017, 7, 28-35.	0.9	18
188	Advances in Prostate Cancer Magnetic Resonance Imaging and Positron Emission Tomography-Computed Tomography for Staging and Radiotherapy Treatment Planning. Seminars in Radiation Oncology, 2017, 27, 21-33.	1.0	24
189	Focal MRI-Guided Salvage High-Dose-Rate Brachytherapy in Patients With Radiorecurrent Prostate Cancer. Technology in Cancer Research and Treatment, 2017, 16, 1194-1201.	0.8	37
190	Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients â‰¥65Âyears old. Radiation Oncology, 2017, 12, 150.	1.2	25
191	The Potential of Heavy-Ion Therapy to Improve Outcomes for Locally Advanced Non-Small Cell Lung Cancer. Frontiers in Oncology, 2017, 7, 201.	1.3	5
192	Second salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer. Journal of Contemporary Brachytherapy, 2017, 2, 161-166.	0.4	10
193	Synchrotron-Based Pencil Beam Scanning Nozzle with an Integrated Mini-Ridge Filter: A Dosimetric Study to Optimize Treatment Delivery. Cancers, 2017, 9, 170.	1.7	4
194	Patterns of locoregional failure following post-operative intensity-modulated radiotherapy to oral cavity cancer: quantitative spatial and dosimetric analysis using a deformable image registration workflow. Radiation Oncology, 2017, 12, 129.	1.2	8
195	Design and fabrication of a 3Dâ€“printed oral stent for head and neck radiotherapy from routine diagnostic imaging. 3D Printing in Medicine, 2017, 3, 12.	1.7	31
196	2017 American Brachytherapy Societyâ€™s Annual Meeting Report. Translational Andrology and Urology, 2017, 6, 1005-1013.	0.6	1
197	Outcomes of oral cavity cancer patients treated with surgery followed by postoperative intensity modulated radiation therapy. Oral Oncology, 2017, 72, 90-97.	0.8	28
198	Intensity-Modulated Proton Therapy Adaptive Planning for Patients with Oropharyngeal Cancer. International Journal of Particle Therapy, 2017, 4, 26-34.	0.9	26

#	Article	IF	Citations
199	Development of a magnetic resonance imaging protocol to visualize encapsulated contrast agent markers in prostate brachytherapy recipients: initial patient experience. Journal of Contemporary Brachytherapy, 2016, 3, 233-240.	0.4	16
200	The MRI-Linear Accelerator Consortium: Evidence-Based Clinical Introduction of an Innovation in Radiation Oncology Connecting Researchers, Methodology, Data Collection, Quality Assurance, and Technical Development. Frontiers in Oncology, 2016, 6, 215.	1.3	100
201	The Influence of Age and Comorbidity on the Benefit of Adding Androgen Deprivation to Dose-escalated Radiation in Men With Intermediate-risk Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 368-373.	0.6	1
202	Radiation therapy (with or without neck surgery) for phenotypic human papillomavirusâ€“associated oropharyngeal cancer. Cancer, 2016, 122, 1702-1707.	2.0	17
203	Merkel cell carcinoma of the head and neck: Favorable outcomes with radiotherapy. Head and Neck, 2016, 38, E452-8.	0.9	32
204	Disease control and toxicity outcomes for T4 carcinoma of the nasopharynx treated with intensityâ€modulated radiotherapy. Head and Neck, 2016, 38, E925-33.	0.9	22
205	Prognostic value of p16 expression in Epsteinâ€Barr virusâ€“positive nasopharyngeal carcinomas. Head and Neck, 2016, 38, E1459-66.	0.9	28
206	Comparison of systemic therapies used concurrently with radiation for the treatment of human papillomavirusâ€“associated oropharyngeal cancer. Head and Neck, 2016, 38, E1554-61.	0.9	11
207	Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma. Head and Neck, 2016, 38, 439-447.	0.9	20
208	Outcomes for hypopharyngeal carcinoma treated with organâ€preservation therapy. Head and Neck, 2016, 38, E2091-9.	0.9	14
209	Communicating Value in Health Care Using Radar Charts: A Case Study of Prostate Cancer. Journal of Oncology Practice, 2016, 12, 813-820.	2.5	44
210	Magnetic Resonance Imaging of Glucose Uptake and Metabolism in Patients with Head and Neck Cancer. Scientific Reports, 2016, 6, 30618.	1.6	62
211	Assessing the Quality of a Radiation Oncology Case-Based, Peer-Review Program in an Integrated Academic and Community Cancer Center Network. Journal of Oncology Practice, 2016, 12, e476-e486.	2.5	19
212	Quantitative analysis of treatment process time and throughput capacity for spot scanning proton therapy. Medical Physics, 2016, 43, 3975-3986.	1.6	17
213	Effect of pulse sequence parameter selection on signal strength in positiveâ€contrast MRI markers for MRIâ€based prostate postimplant assessment. Medical Physics, 2016, 43, 4312-4322.	1.6	15
214	A Multidisciplinary Orbit-Sparing Treatment Approach That Includes Proton Therapy for Epithelial Tumors of the Orbit and Ocular Adnexa. International Journal of Radiation Oncology Biology Physics, 2016, 95, 344-352.	0.4	49
215	Magnetic resonance imaging of swallowing-related structures in nasopharyngeal carcinoma patients receiving IMRT: Longitudinal doseâ€“response characterization of quantitative signal kinetics. Radiotherapy and Oncology, 2016, 118, 315-322.	0.3	21
216	The role of elective nodal irradiation for esthesioneuroblastoma patients with clinically negative neck. Practical Radiation Oncology, 2016, 6, 241-247.	1.1	41

#	Article	IF	Citations
217	Beyond mean pharyngeal constrictor dose for beam path toxicity in non-target swallowing muscles: Doseâ€“volume correlates of chronic radiation-associated dysphagia (RAD) after oropharyngeal intensity modulated radiotherapy. Radiotherapy and Oncology, 2016, 118, 304-314.	0.3	85
218	Intensity Modulated Proton Therapy for Head and Neck Tumors: Gilding the Lily or Holy Grail?. International Journal of Radiation Oncology Biology Physics, 2016, 95, 37-39.	0.4	7
219	Reirradiation of Head and Neck Cancers With Proton Therapy: Outcomes and Analyses. International Journal of Radiation Oncology Biology Physics, 2016, 96, 30-41.	0.4	123
220	Outcomes after adjuvant radiation therapy for prostate cancer at a comprehensive cancer center. Journal of Radiation Oncology, 2016, 5, 287-292.	0.7	0
221	Permanent Seed Implantation Prostate Brachytherapy for Intermediate Risk Prostate Cancer: Efficacy and Toxicity Outcomes from a Prospective Cohort of 300 Patients. Brachytherapy, 2016, 15, S201.	0.2	1
222	Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer â€“ A case matched analysis. Radiotherapy and Oncology, 2016, 120, 48-55.	0.3	177
223	Toward a model-based patient selection strategy for proton therapy: External validation of photon-derived normal tissue complication probability models in a head and neck proton therapy cohort. Radiotherapy and Oncology, 2016, 121, 381-386.	0.3	78
224	Assessing head and neck cancer patient preferences and expectations: A systematic review. Oral Oncology, 2016, 62, 44-53.	0.8	39
225	Longâ€term outcomes after multidisciplinary management of T3 laryngeal squamous cell carcinomas: Improved functional outcomes and survival with modern therapeutic approaches. Head and Neck, 2016, 38, 1739-1751.	0.9	33
226	Biological responses of human solid tumor cells to Xâ€ray irradiation within a 1.5â€Tesla magnetic field generated by a magnetic resonance imagingâ€“linear accelerator. Bioelectromagnetics, 2016, 37, 471-480.	0.9	12
227	Reply to radiotherapy for human papillomavirusâ€positive oropharyngeal cancers in the National Cancer Data Base. Cancer, 2016, 122, 3411-3412.	2.0	1
228	Intensityâ€modulated proton therapy for nasopharyngeal carcinoma: Decreased radiation dose to normal structures and encouraging clinical outcomes. Head and Neck, 2016, 38, E1886-95.	0.9	102
229	Disease reclassification risk with stringent criteria and frequent monitoring in men with favourableâ€risk prostate cancer undergoing active surveillance. BJU International, 2016, 118, 68-76.	1.3	27
230	Dosimetric advantages of intensity-modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation: A case-matched control analysis. Medical Dosimetry, 2016, 41, 189-194.	0.4	62
231	Orbital carcinomas treated with adjuvant intensityâ€modulated radiation therapy. Head and Neck, 2016, 38, E580-7.	0.9	10
232	Definitive proton radiation therapy and concurrent cisplatin for unresectable head and neck adenoid cystic carcinoma: A series of 9 cases and a critical review of the literature. Head and Neck, 2016, 38, E1472-80.	0.9	36
233	Eyeâ€sparing multidisciplinary approach for the management of lacrimal gland carcinoma. Head and Neck, 2016, 38, 1258-1262.	0.9	46
234	Reirradiation of Head and Neck Cancers With Intensity Modulated Radiation Therapy: Outcomes and Analyses. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1117-1131.	0.4	100

#	Article	IF	Citations
235	Association of Body Composition With Survival and Locoregional Control of Radiotherapy-Treated Head and Neck Squamous Cell Carcinoma. JAMA Oncology, 2016, 2, 782.	3.4	185
236	Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1107-1114.	0.4	121
237	Clinical Outcomes and Patterns of Disease Recurrence After Intensity Modulated Proton Therapy for Oropharyngeal Squamous Carcinoma. International Journal of Radiation Oncology Biology Physics, 2016, 95, 360-367.	0.4	88
238	Defining the value framework for prostate brachytherapy using patient-centered outcome metrics and time-driven activity-based costing. Brachytherapy, 2016, 15, 274-282.	0.2	37
239	Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourableâ€risk prostate cancer undergoing active surveillance. BJU International, 2016, 117, 469-477.	1.3	81
240	Novel Hybrid Scattering- and Scanning-Beam Proton Therapy Approach. International Journal of Particle Therapy, 2016, 3, 37-50.	0.9	2
241	Variations in Proton Therapy Coverage in the State of Texas: Defining Medical Necessity for a Safe and Effective Treatment. International Journal of Particle Therapy, 2016, 2, 499-508.	0.9	4
242	Postoperative Intensity-Modulated Proton Therapy for Head and Neck Adenoid Cystic Carcinoma. International Journal of Particle Therapy, 2016, 2, 533-543.	0.9	16
243	Proton Beam Therapy for Localized Prostate Cancer: Results from a Prospective Quality-of-Life Trial. International Journal of Particle Therapy, 2016, 3, 27-36.	0.9	14
244	Robust Optimization for Intensity Modulated Proton Therapy Plans with Multi-Isocenter Large Fields. International Journal of Particle Therapy, 2016, 3, 305-311.	0.9	7
245	Proton therapy for nasopharyngeal carcinoma. Chinese Clinical Oncology, 2016, 5, 25-25.	0.4	33
246	Reduced acute toxicity and improved efficacy from intensity-modulated proton therapy (IMPT) for the management of head and neck cancer. Chinese Clinical Oncology, 2016, 5, 54-54.	0.4	23
247	Evaluation of the MIM Symphony treatment planning system for lowâ€doseâ€rateâ€prostate brachytherapy. Journal of Applied Clinical Medical Physics, 2015, 16, 62-75.	0.8	9
248	Intravoxel incoherent motion imaging kinetics during chemoradiotherapy for human papillomavirus-associated squamous cell carcinoma of the oropharynx: preliminary results from a prospective pilot study. NMR in Biomedicine, 2015, 28, 1645-1654.	1.6	51
249	Towards Effective and Efficient Patient-Specific Quality Assurance for Spot Scanning Proton Therapy. Cancers, 2015, 7, 631-647.	1.7	59
250	Prospective observer and software-based assessment of magnetic resonance imaging quality in head and neck cancer: Should standard positioning and immobilization be required for radiation therapy applications?. Practical Radiation Oncology, 2015, 5, e299-e308.	1.1	31
251	Sexual potency preservation and quality of life after prostate brachytherapy and low-dose tadalafil. Brachytherapy, 2015, 14, 160-165.	0.2	14
252	Early experience with intensity modulated proton therapy for lung-intact mesothelioma: A case series. Practical Radiation Oncology, 2015, 5, e345-e353.	1.1	40

#	Article	IF	Citations
253	Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer. European Urology, 2015, 67, 460-467.	0.9	190
254	Risk Factors and Prognosis for Myoepithelial Carcinoma of the Major Salivary Glands. Annals of Surgical Oncology, 2015, 22, 3701-3707.	0.7	20
255	Characteristics and kinetics of cervical lymph node regression after radiation therapy for human papillomavirus-associated oropharyngeal carcinoma: Quantitative image analysis of post-radiotherapy response. Oral Oncology, 2015, 51, 195-201.	0.8	13
256	Quality Assurance Assessment of Diagnostic and Radiation Therapyâ€“Simulation CT Image Registration for Head and Neck Radiation Therapy: Anatomic Region of Interestâ€“based Comparison of Rigid and Deformable Algorithms. Radiology, 2015, 274, 752-763.	3.6	58
257	Prognostic factors in adenocarcinoma of the salivary glands. Oral Oncology, 2015, 51, 610-615.	0.8	30
258	Proton therapy for seminoma: Case report describing the technique, efficacy, and advantages of proton-based therapy for seminoma. Practical Radiation Oncology, 2015, 5, 135-140.	1.1	5
259	Favorable patient reported outcomes following IMRT for early carcinomas of the tonsillar fossa: Results from a symptom assessment study. Radiotherapy and Oncology, 2015, 117, 132-138.	0.3	21
260	Brachytherapy: Where Has It Gone?. Journal of Clinical Oncology, 2015, 33, 980-982.	0.8	102
261	Metabolic Imaging as a Biomarker of Early Radiation Response in Tumors. Clinical Cancer Research, 2015, 21, 4996-4998.	3.2	10
262	Comparative costs of advanced proton and photon radiation therapies: lessons from time-driven activity-based costing in head and neck cancer. Journal of Comparative Effectiveness Research, 2015, 4, 297-301.	0.6	25
263	Impact of Insurance Status on Radiation Treatment Modality Selection Among Potential Candidates for Prostate, Breast, or Gynecologic Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2015, 93, 968-975.	0.4	22
264	Proton Therapy Reduces Treatment-Related Toxicities for Patients with Nasopharyngeal Cancer: A Case-Match Control Study of Intensity-Modulated Proton Therapy and Intensity-Modulated Photon Therapy. International Journal of Particle Therapy, 2015, 2, 19-28.	0.9	76
265	Correlation of American Joint Committee on Cancer T Category for Eyelid Carcinoma With Outcomes in Patients With Periocular Merkel Cell Carcinoma. Ophthalmic Plastic and Reconstructive Surgery, 2014, 30, 480-485.	0.4	19
266	ACR Appropriateness CriteriaÂ® Definitive External-Beam Irradiation in Stage T1 and T2 Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 278-288.	0.6	13
267	Nomogram for Predicting Symptom Severity during Radiation Therapy for Head and Neck Cancer. Otolaryngology - Head and Neck Surgery, 2014, 151, 619-626.	1.1	18
268	A single-field integrated boost treatment planning technique for spot scanning proton therapy. Radiation Oncology, 2014, 9, 202.	1.2	24
269	Beam path toxicity in candidate organs-at-risk: Assessment of radiation emetogenesis for patients receiving head and neck intensity modulated radiotherapy. Radiotherapy and Oncology, 2014, 111, 281-288.	0.3	54
270	Oncology Scanâ€”Demonstrating Technology and Measuring Outcomes in Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 88, 759-760.	0.4	4

#	Article	IF	Citations
271	Auto-segmentation of low-risk clinical target volume for head and neck radiation therapy. Practical Radiation Oncology, 2014, 4, e31-e37.	1.1	28
272	MRI characterization of cobalt dichloride-N-acetyl cysteine (C4) contrast agent marker for prostate brachytherapy. Physics in Medicine and Biology, 2014, 59, 2505-2516.	1.6	21
273	Establishing High-Quality Prostate Brachytherapy Using a Phantom Simulator Training Program. International Journal of Radiation Oncology Biology Physics, 2014, 90, 579-586.	0.4	43
274	Management of the lymph nodeâ€positive neck in the patient with human papillomavirusâ€associated oropharyngeal cancer. Cancer, 2014, 120, 3082-3088.	2.0	27
275	ACR Appropriateness Criteria high-dose-rate brachytherapy for prostate cancer. Brachytherapy, 2014, 13, 27-31.	0.2	24
276	MRI-based sector analysis enhances prostate palladium-103 brachytherapy quality assurance in a phase II prospective trial of men with intermediate-risk localized prostate cancer. Brachytherapy, 2014, 13, 68-74.	0.2	6
277	Dosimetric influence of seed spacers and end-weld thickness for permanent prostate brachytherapy. Brachytherapy, 2014, 13, 304-310.	0.2	8
278	Risk of Late Toxicity in Men Receiving Dose-Escalated Hypofractionated Intensity Modulated Prostate Radiation Therapy: Results From a Randomized Trial. International Journal of Radiation Oncology Biology Physics, 2014, 88, 1074-1084.	0.4	127
279	Declining use of brachytherapy for the treatment of prostate cancer. Brachytherapy, 2014, 13, 157-162.	0.2	67
280	Magnetic Resonance Image Guided Brachytherapy. Seminars in Radiation Oncology, 2014, 24, 181-191.	1.0	101
281	Response to Drs Rogers, Hayes, and Demanes. Brachytherapy, 2014, 13, 523-525.	0.2	0
282	Multifield Optimization Intensity Modulated Proton Therapy for Head and Neck Tumors: A Translation to Practice. International Journal of Radiation Oncology Biology Physics, 2014, 89, 846-853.	0.4	128
283	Proton Radiation Therapy for Head and Neck Cancer: A Review of the Clinical Experience to Date. International Journal of Radiation Oncology Biology Physics, 2014, 89, 292-302.	0.4	104
284	Spot-Scanning Proton Therapy Patient-Specific Quality Assurance: Results from 309 Treatment Plans. International Journal of Particle Therapy, 2014, 1, 711-720.	0.9	20
285	High symptom burden prior to radiation therapy for head and neck cancer: A patientâ€reported outcomes study. Head and Neck, 2013, 35, 1490-1498.	0.9	48
286	Outcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21st century. Radiation Oncology, 2013, 8, 21.	1.2	89
287	Preliminary evaluation of multifield and single-field optimization for the treatment planning of spot-scanning proton therapy of head and neck cancer. Medical Physics, 2013, 40, 081709.	1.6	68
288	Patterns of Disease Recurrence Following Treatment of Oropharyngeal Cancer With Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 85, 941-947.	0.4	99

#	Article	IF	Citations
289	Spot-scanning beam proton therapy vs intensity-modulated radiation therapy for ipsilateral head and neck malignancies: A treatment planning comparison. Medical Dosimetry, 2013, 38, 390-394.	0.4	88
290	Quality of Life and Toxicity From Passively Scattered and Spot-Scanning Proton Beam Therapy for Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 87, 946-953.	0.4	38
291	Advances in Radiation Oncology for the Management of Oropharyngeal Tumors. Otolaryngologic Clinics of North America, 2013, 46, 629-643.	0.5	8
292	PSA Response to Neoadjuvant Androgen Deprivation Therapy Is a Strong Independent Predictor of Survival in High-Risk Prostate Cancer in the Dose-Escalated Radiation Therapy Era. International Journal of Radiation Oncology Biology Physics, 2013, 85, e39-e46.	0.4	24
293	A Biodistribution and Toxicity Study of Cobalt Dichloride-N-Acetyl Cysteine in an Implantable MRI Marker for Prostate Cancer Treatment. International Journal of Radiation Oncology Biology Physics, 2013, 85, 1024-1030.	0.4	16
294	Endorectal magnetic resonance imaging for predicting pathologic T3Âdisease in Gleason score 7Âprostate cancer: Implications forÂprostateÂbrachytherapy. Brachytherapy, 2013, 12, 204-209.	0.2	21
295	Is Androgen Deprivation Therapy Necessary in All Intermediate-Risk Prostate Cancer Patients Treated in the Dose Escalation Era?. International Journal of Radiation Oncology Biology Physics, 2013, 85, 693-699.	0.4	51
296	Magnetic resonance imaging-based treatment planning for prostate brachytherapy. Brachytherapy, 2013, 12, 30-37.	0.2	37
297	An MRI-based doseâ€“response analysis of urinary sphincter dose and urinary morbidity after brachytherapy for prostate cancer in a phase II prospective trial. Brachytherapy, 2013, 12, 210-216.	0.2	22
298	Improving prostate brachytherapy quality assurance with MRIâ€“CT fusionâ€“based sector analysis in a phase II prospective trial of men with intermediate-risk prostate cancer. Brachytherapy, 2013, 12, 401-407.	0.2	16
299	ACR Appropriateness Criteria Prostate Cancerâ€”Pretreatment Detection, Staging, and Surveillance. Journal of the American College of Radiology, 2013, 10, 83-92.	0.9	65
300	MR Imaging of Prostate Cancer in Radiation Oncology: What Radiologists Need to Know. Radiographics, 2013, 33, 741-761.	1.4	46
301	Multidisciplinary Management of Lacrimal Sac/Nasolacrimal Duct Carcinomas. Ophthalmic Plastic and Reconstructive Surgery, 2013, 29, 454-457.	0.4	50
302	Effectiveness of robust optimization in intensityâ€modulated proton therapy planning for head and neck cancers. Medical Physics, 2013, 40, 051711.	1.6	135
303	Primary intestinalâ€like adenocarcinoma of major salivary glands: 2 instances of previously undocumented phenotype. Head and Neck, 2013, 35, E234-6.	0.9	13
304	Longâ€term outcomes for men with highâ€risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation. Cancer, 2013, 119, 3265-3271.	2.0	43
305	The impact of radiographic retropharyngeal adenopathy in oropharyngeal cancer. Cancer, 2013, 119, 3162-3169.	2.0	49
306	Multidisciplinary Management of Primary Adenoid Cystic Carcinoma of the Eyelid With Perineural Invasion. Ophthalmic Plastic and Reconstructive Surgery, 2013, 29, e143-e146.	0.4	5

#	Article	IF	Citations
307	A novel doseâ€based positioning method for CT imageâ€guided proton therapy. Medical Physics, 2013, 40, 051714.	1.6	13
308	PTV-based IMPT optimization incorporating planning risk volumes vs robust optimization. Medical Physics, 2013, 40, 021709.	1.6	74
309	TU-G-134-05: MRI Characteristics of Cobalt Dichloride N-Acetyl Cysteine (C4) as a Contrast Agent Marker for Prostate Brachytherapy. Medical Physics, 2013, 40, 461-461.	1.6	0
310	Improvement in Prostate Cancer Survival Over Time. Cancer Journal (Sudbury, Mass), 2012, 18, 1-8.	1.0	34
311	Prostate Specific Antigen Bounce Is Related to Overall Survival in Prostate Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2012, 82, 883-888.	0.4	45
312	Unilateral Radiotherapy for the Treatment of Tonsil Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 83, 204-209.	0.4	94
313	Sexual Function and the Use of Medical Devices or Drugs to Optimize Potency After Prostate Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2012, 82, e765-e771.	0.4	10
314	ACR Appropriateness CriteriaÂ® External-Beam Radiation Therapy Treatment Planning for Clinically Localized Prostate Cancer. Journal of the American College of Radiology, 2012, 9, 233-238.	0.9	10
315	Prostate cancer-specific mortality after definitive radiation therapy: Who dies of disease?. European Journal of Cancer, 2012, 48, 1664-1671.	1.3	16
316	Dosimetric impact of fiducial markers in patients undergoing photon beam radiation therapy. Physica Medica, 2012, 28, 240-244.	0.4	11
317	Preoperative treatment planning with intraoperative optimization can achieve consistent high-quality implants in prostate brachytherapy. Medical Dosimetry, 2012, 37, 387-390.	0.4	6
318	Knife or needles? A cohort analysis of outcomes after radical prostatectomy or brachytherapy for men with low- or intermediate-risk adenocarcinoma of the prostate. Brachytherapy, 2012, 11, 429-434.	0.2	12
319	Screening colonoscopy before prostate cancer treatment can detect colorectal cancers in asymptomatic patients and reduce the rate of complications after brachytherapy. Practical Radiation Oncology, 2012, 2, e7-e13.	1.1	8
320	Comparative analysis of prostateâ€specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU International, 2012, 109, 22-29.	1.3	391
321	Outcomes after prostate brachytherapy are even better than predicted. Cancer, 2012, 118, 839-847.	2.0	24
322	Effect of adding short-term androgen deprivation therapy to dose-escalated radiation therapy on failure-free survival for select men with intermediate-risk prostate cancer.. Journal of Clinical Oncology, 2012, 30, 176-176.	0.8	0
323	American College of Radiology Appropriateness Criteria permanent source brachytherapy for prostate cancer. Brachytherapy, 2011, 10, 357-362.	0.2	28
324	Displacement of periurethral stranded seeds and its dosimetric consequences in prostate brachytherapy. Brachytherapy, 2011, 10, 401-408.	0.2	7

#	Article	IF	Citations
325	Management of Perineural Invasion in Sebaceous Carcinoma of the Eyelid. Ophthalmic Plastic and Reconstructive Surgery, 2011, 27, 356-359.	0.4	27
326	Positive Sentinel Node in Sebaceous Carcinoma of the Eyelid. Ophthalmic Plastic and Reconstructive Surgery, 2011, 27, e4-e6.	0.4	33
327	Subacute penile numbness after brachytherapy for prostate cancer. Brachytherapy, 2011, 10, 64-67.	0.2	0
328	Outcomes of malignant tumors of the lacrimal apparatus. Cancer, 2011, 117, 2801-2810.	2.0	62
329	Long-Term Failure Patterns and Survival in a Randomized Dose-Escalation Trial for Prostate Cancer. Who Dies of Disease?. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1310-1317.	0.4	229
330	Impact of urinary catheterization on dosimetry after prostate implant brachytherapy with palladium-103 or iodine-125. Brachytherapy, 2011, 10, 269-274.	0.2	4
331	Anisotropy Characterization of I-125 Seed with Attached Encapsulated Cobalt Chloride Complex Contrast Agent Markers for MRI-Based Prostate Brachytherapy. Medical Dosimetry, 2011, 36, 200-205.	0.4	12
332	Clinical Investigations Long-term tumor control after brachytherapy for base of prostate cancer. Journal of Contemporary Brachytherapy, 2011, 4, 183-187.	0.4	7
333	ACR Appropriateness CriteriaÂ® Definitive External Beam Irradiation in Stage T1 and T2 Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 636-647.	0.6	3
334	ACR Appropriateness CriteriaÂ® Postradical Prostatectomy Irradiation in Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 92-98.	0.6	14
335	Health-Related Quality of Life up to Six Years After 125I Brachytherapy for Early-Stage Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 76, 1054-1060.	0.4	39
336	Long-Term Biochemical and Survival Outcome of 921 Patients Treated With I-125 Permanent Prostate Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2010, 76, 1433-1438.	0.4	120
337	Proton Beam Radiation Therapy for Head and Neck Malignancies. Current Oncology Reports, 2010, 12, 202-207.	1.8	29
338	Simple Carotid-Sparing Intensity-Modulated Radiotherapy Technique and Preliminary Experience for T1â€“2 Glottic Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 77, 455-461.	0.4	89
339	The Impact of Acute Urinary Retention After Iodine-125 Prostate Brachytherapy on Health-Related Quality of Life. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1322-1328.	0.4	22
340	Prospective Imaging Assessment of Mortality Risk After Head-and-Neck Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2010, 78, 667-674.	0.4	21
341	Intensity-Modulated Radiotherapy for Cervical Node Squamous Cell Carcinoma Metastases From Unknown Head-and-Neck Primary Site: M. D. Anderson Cancer Center Outcomes and Patterns of Failure. International Journal of Radiation Oncology Biology Physics, 2010, 78, 1005-1010.	0.4	75
342	Radiation Therapy for Orbital and Adnexal Tumors. , 2010, , 169-175.		0

#	Article	IF	Citations
343	A Volumetric Trend Analysis of the Prostate and Seminal Vesicles During a Course of Intensity-Modulated Radiation Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 173-175.	0.6	7
344	Late rectal complications after prostate brachytherapy for localized prostate cancer. Cancer, 2009, 115, 1827-1839.	2.0	80
345	Urinary Side Effects and Complications After Permanent Prostate Brachytherapy: The MD Anderson Cancer Center Experience. Urology, 2009, 74, 601-605.	0.5	59
346	Prospective Risk-Adjusted [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography Assessment of Radiation Response in Head and Neck Cancer. Journal of Clinical Oncology, 2009, 27, 2509-2515.	0.8	156
347	Prostogram Predicted Brachytherapy Outcomes are Not Universally Accurate: An Analysis Based on the M. D. Anderson Cancer Center Experience With 125 Iodine Brachytherapy. Journal of Urology, 2009, 181, 1658-1664.	0.2	7
348	Variations in proton scanned beam dose delivery due to uncertainties in magnetic beam steering. Medical Physics, 2009, 36, 3693-3702.	1.6	16
349	Outcomes after radiotherapy for squamous cell carcinoma of the eyelid. Cancer, 2008, 112, 111-118.	2.0	56
350	Treatment of recurrent vaginal melanoma with external beam radiation therapy and palladium-103 brachytherapy. Brachytherapy, 2008, 7, 359-363.	0.2	9
351	Quantification of Prostate and Seminal Vesicle Interfraction Variation During IMRT. International Journal of Radiation Oncology Biology Physics, 2008, 71, 813-820.	0.4	74
352	A Novel MRI Marker for Prostate Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2008, 71, 5-8.	0.4	48
353	Is a Loose-Seed Nomogram Still Valid for Prostate Brachytherapy in a Stranded-Seed Era?. International Journal of Radiation Oncology Biology Physics, 2008, 72, 623-627.	0.4	15
354	PROSTATE BRACHYTHERAPY â€“ THE M.D. ANDERSON CANCER CENTER EXPERIENCE. Journal of Urology, 2008, 179, 396-397.	0.2	4
355	Postoperative Adjuvant External-Beam Radiation Therapy for Cancers of the Eyelid and Conjunctiva. Ophthalmic Plastic and Reconstructive Surgery, 2008, 24, 444-449.	0.4	45
356	An Assessment of Quality of Life Following Radical Prostatectomy, High Dose External Beam Radiation Therapy and Brachytherapy Iodine Implantation as Monotherapies for Localized Prostate Cancer. Journal of Urology, 2007, 177, 2151-2156.	0.2	129
357	Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics, 2007, 67, 1059-1065.	0.4	127
358	Reduce in Variation and Improve Efficiency of Target Volume Delineation by a Computer-Assisted System Using a Deformable Image Registration Approach. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1512-1521.	0.4	113
359	Primary adenocarcinoma of the vagina not associated with diethylstilbestrol (DES) exposure. Gynecologic Oncology, 2007, 105, 470-474.	0.6	70
360	Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: A survey of practice patterns in the United States. Brachytherapy, 2007, 6, 2-8.	0.2	47

#	Article	IF	Citations
361	Update on Radiation Therapy in Prostate Cancer. Hematology/Oncology Clinics of North America, 2006, 20, 857-878.	0.9	5
362	Results of the 2004 Association of Residents in Radiation Oncology (ARRO) Survey. International Journal of Radiation Oncology Biology Physics, 2006, 66, 1199-1203.	0.4	22
363	Results of the 2003 Association of Residents in Radiation Oncology (ARRO) surveys of residents and chief residents in the United States. International Journal of Radiation Oncology Biology Physics, 2005, 61, 642-648.	0.4	28
364	Definitive radiation therapy for squamous cell carcinoma of the vagina. International Journal of Radiation Oncology Biology Physics, 2005, 62, 138-147.	0.4	181
365	Technology Insight: PET and PET/CT in head and neck tumor staging and radiation therapy planning. Nature Clinical Practice Oncology, 2005, 2, 526-533.	4.3	34
366	Self-Referral: What Residents Need To Know. Journal of the American College of Radiology, 2005, 2, 452-454.	0.9	1
367	Heterogeneous planning for homogeneous protocols. Medical Dosimetry, 2004, 29, 80-84.	0.4	0
368	Advances in Radiation Treatments of Breast Cancer. Clinical Breast Cancer, 2004, 4, 401-406.	1.1	5
369	Treatment planning for lung cancer: Traditional homogeneous pointâ€“dose prescription compared with heterogeneity-corrected doseâ€“volume prescription. International Journal of Radiation Oncology Biology Physics, 2003, 56, 1308-1318.	0.4	28